ProMIS Neurosciences at Moody Capital conference: safety sets it apart

On Thursday, September 10, 2026, ProMIS Neurosciences (PMN) presented its differentiated Alzheimer's drug candidate, PMN310, at the Moody Capital Disruptive Growth & Life Science Conference. The company showcased encouraging interim safety and biomarker data for PMN310 while acknowledging the uncertain market sentiment and its current low stock price of $13.49.

PMN310 is a second-generation monoclonal antibody in a Phase 1b trial for early Alzheimer's disease, including patients with mild cognitive impairment. The interim analysis, conducted on July 28, showed no amyloid-related imaging abnormalities (ARIA-E) and no treatment-related serious adverse events or dropouts. PMN310 targets toxic oligomers of beta-amyloid, avoiding plaque and monomers that plague current therapies.

The company reported a 15% decline in p-tau217, a biomarker tied to Alzheimer's progression, and the trend moved in the desired direction. ProMIS stated that its financial position is strong and well-positioned to support the next data readouts through Q1 2027 when final Phase 1b results are expected. The CEO, Neil Warma, emphasized that ProMIS's approach is based on computational modeling to predict protein misfolding and design antibodies against harmful forms of beta-amyloid.